Results 41 to 50 of about 1,337,415 (292)

Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy [PDF]

open access: yes, 2018
The combination of different therapies into a single platform has attracted increasing attention as a potential synergistic tumor treatment. Herein, the fabrication of a novel folate targeted system for chemo-photothermal therapy by using thioether ...
Bremner, David H.   +7 more
core   +1 more source

Advances in drug delivery system for platinum agents based combination therapy

open access: yesCancer Biology & Medicine, 2015
Platinum-based anticancer agents are widely used as first-line drugs in cancer chemotherapy for various solid tumors. However, great side effects and occurrence of resistance remain as the major drawbacks for almost all the platinum drugs developed.
Xiang Kang   +5 more
doaj   +1 more source

Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model [PDF]

open access: yes, 2016
Infections with Plasmodium falciparum, the most pathogenic of the Plasmodium species affecting man, have been reduced in part due to artemisinin-based combination therapies.
Baro, Nicholas   +14 more
core   +1 more source

Comparison of Single vs Combination Drug Therapy in Extensively Drug Resistant Salmonella typhi: An Observational Study from Pakistan

open access: yesInfection and Drug Resistance, 2022
Sadia Ishaque,1,2 Beenish Syed,1,3 Sunil Kumar Dodani,4 Sana Anwar5 1Department of Medicine, Liaquat National Hospital, Karachi, Pakistan; 2Department of Infectious Disease Shaheed Mohtarma, Benazir Bhutto Institute of Trauma, Dow University of Health ...
Ishaque S, Syed B, Dodani SK, Anwar S
doaj  

Disseminated Rhodococcus equi infection in a patient with Hodgkin’s lymphoma [PDF]

open access: yesVojnosanitetski Pregled, 2014
Introduction. Rhodococcus (R) equi is an opportunistic, uncommon human pathogen that causes mainly infection in immunocompromised hosts. The disease is usually presented as subacute pneumonia that is mostly cavitary and sometimes bacteremic ...
Mikić Dragan   +3 more
doaj   +1 more source

Combination of tocainide and quinidine for better tolerance and additive effects in patients with coronary artery disease [PDF]

open access: yes, 1987
The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (≥30/h) ventricular premature complexes.
Fisher, John D.   +2 more
core   +1 more source

FoxO1 signaling in B cell malignancies and its therapeutic targeting

open access: yesFEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac   +3 more
wiley   +1 more source

Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria [PDF]

open access: yes, 2008
Besides existing artemisinin-based combination therapies, alternative safe, effective and affordable drug combinations against falciparum malaria are needed. Methylene blue (MB) was the first synthetic antimalarial drug ever used, and recent studies have
Coulibaly, Boubacar   +10 more
core   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

open access: yesFEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Drug combination therapy for emerging viral diseases

open access: yesDrug Discovery Today, 2021
Effective therapeutics to combat emerging viral infections are an unmet need. Historically, treatments for chronic viral infections with single drugs have not been successful, as exemplified by human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections.
Zeenat A. Shyr   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy